Efgartigimod as maintenance treatment after a myasthenia gravis crisis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of myasthenia gravis and are positive for AChR antibodies.
- You were recently hospitalized for a myasthenia gravis crisis and completed one cycle of efgartigimod (4 weekly IV doses).
- Your symptoms improved by at least 2 points on a standard myasthenia gravis scale after starting efgartigimod.
- You have not had certain other treatments (like IVIg, plasma exchange, or high-dose steroids) in the past month.
- You are not pregnant or breastfeeding and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This study looks at how safe efgartigimod is for people with generalized myasthenia gravis (gMG), whether they are taking the drug now, will start it soon, or are not taking it at all.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests the drug efgartigimod given before and after surgery for people with myasthenia gravis and a thymoma. The goal is to see if it helps improve symptoms and recovery around the operation.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.